Subscribe to Journal
Get full journal access for 1 year
only $20.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Mossinghoff, G. J. Food Drug Law J. 54, 187–194 (1999).
Dunn, M. K. Nat. Rev. Drug Discov. 10, 487–488 (2011).
Pew Charitable Trusts. Policy proposal: reducing the exclusivity period for biological products. https://www.pewtrusts.org/-/media/assets/2017/09/dsri_policy_proposal_reducing_the_exclusivity_period_for_biological_products.pdf (2017).
Husser, A. Will USMCA affect Canada’s drug prices? Depends on what happens next, experts say. https://www.cbc.ca/news/health/usmca-pharma-drugs-prices-cost-1.4846421 (2018).
PhRMA. Response to request for comments on negotiating objectives for a U.S.–Japan trade agreement, 83 Fed. Reg. 54,164 (October 26, 2018). http://phrma-docs.phrma.org/files/dmfile/PhRMA-Comments-on-Negotiating-Objectives-for-U.S.-Japan-Trade-Agreement.pdf (2018).
AARP. 2018 Federal Priorities Letter to OMB. https://www.aarp.org/content/dam/aarp/politics/advocacy/2018/01/01-23-18-2018-federal-priorities-letter-final.pdf (2018).
United States Office of Management and Budget. Meeting our greatest challenges: opportunity for all. https://obamawhitehouse.archives.gov/sites/default/files/omb/budget/fy2017/assets/opportunity.pdf (2017).
Roy, A. A market-based plan for affordable prescription drugs. https://freopp.org/a-market-based-plan-for-affordable-prescription-drugs-931e31024e08 (2017).
Mestre-Ferrandiz, J., Sussex, J. & Towse A. The R&D cost of a new medicine. https://EconPapers.repec.org/RePEc:ohe:monogr:000135 (2012).
DiMasi, J.A. & Grabowski, H.G. The cost of biopharmaceutical R&D: is biotech different? MDE Manage. Decis. Econ. 28, 469–479 (2007).
Beall, R.F., Hwang, T.J. & Kesselheim, A.S. Major events in the life course of new drugs, 2000–2016. N. Engl. J. Med. 380, e12 (2019).
United States Food and Drug Administration. CDEr list of licensed biological products with (1) reference product exclusivity and (2) biosimilarity or interchangeability evaluations to date. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM560162.pdf (2018).
Zhou, S. & Johnson, R. Pharmaceutical probability of success. https://cdn2.hubspot.net/hubfs/3828687/Alacrita_April2019/PDF/Pharmaceutical-Probability-of-Success.pdf (2018).
Nocera, J. Drug-price transparency won’t end the patent games. https://www.bloomberg.com/opinion/articles/2018-10-16/humira-patents-show-why-fda-s-drug-price-shaming-won-t-work (2018).
United States Food and Drug Administration. New drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/default.htm (2018).
United States Food and Drug Administration. Drugs@FDA: FDA approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/ (2017).
United States Patent and Trade Office. Patent Terms Extended Under 35 USC §156. https://www.uspto.gov/patent/laws-and-regulations/patent-term-extension/patent-terms-extended-under-35-usc-156 (2017).
Beall, R.F., Darrow, J.J. & Kesselheim, A.S. Value Health 21, 1382–1389 (2018).
Beall, R.F., Darrow, J.J. & Kesselheim, A.S. Drug Discov. Today 24, 20–25 (2019).
Hemphill, C. S. & Sampat, B. N. J. Health Econ. 31, 327–339 (2012).
Royal Society of Chemistry. The Merck Index Online https://www.rsc.org/merck-index/search (2018).
European Patent Office. Espacenet Patent Search https://worldwide.espacenet.com/ (2018).
United States Food and Drug Administration. Advancing health through innovation — 2017 new drug therapy approvals. https://www.fda.gov/files/about%20fda/published/2017-New-Drug-Therapy-Approvals-Report.pdf (2017).
The authors thank the US Patent and Trademark Office for providing access to patent term restoration data. A.S.K.’s work is supported by Arnold Ventures, the Harvard–MIT Center for Regulatory Science, and the Engelberg Foundation.
The authors declare no competing interests.
Editor’s note: This article has been peer-reviewed.
About this article
Cite this article
Beall, R.F., Hwang, T.J. & Kesselheim, A.S. Pre-market development times for biologic versus small-molecule drugs. Nat Biotechnol 37, 708–711 (2019). https://doi.org/10.1038/s41587-019-0175-2
Investigating Rates of Food and Drug Administration Approvals and Guidances in Drug Development: A Structural Breakpoint/Cointegration Timeseries Analysis
Therapeutic Innovation & Regulatory Science (2020)
Expert Opinion on Biological Therapy (2020)
Journal of the American Academy of Dermatology (2020)
The Journal of Law, Medicine & Ethics (2019)
How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?
Health Policy (2019)